Big Pharma companies rarely move their stock in a significant positive direction with earnings, so a quite quarter at Pfizer (PFE)
is perfectly fine. It's worth noting, though, that brutal cost-cutting
measures are paying off in terms of excellent operating margins. If
Pfizer can wring success out of its maturing late-stage pipeline, this
could once again be a full-fledged blue-chip stock.
Click here for more:
Nothing Wrong With A Quiet Quarter At Pfizer
No comments:
Post a Comment